HYLOMORPH closes CHF 3.2 millions Series A funding

HYLOMORPH, an ETH Zurich spin-off and Medtech startup, closes its Series A financing round with CHF 3.2 million.

The funding will allow the startup company to finalize product development and conduct clinical studies required for FDA approval and CE certification expected in 2021.

Recommended News

Sign up for our newsletter!

For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.